Table 3.
Adverse effects after 1st and 2nd dose of COVID-19 mRNA BNT162b2 vaccine (n =278)
| Adverse effect | 1st Dose n (%) | 2nd Dose n (%) | P | |
|---|---|---|---|---|
| None | 31 (11.15) | 27(9.71) | 0.48 | |
| Local erythema | 35 (12.59) | 30 (10.79) | 0.25 | |
| Local swelling | 51 (18.35) | 51 (18.35) | 1 | |
| Local pain | 232 (83.45) | 217 (78.06) | 0.025 | |
| Low grade fever (under 38ºC) | 18 (6.47) | 62 (22.30) | <0.0001 | |
| Fever >38ºC & < 39ºC | 6 (2.16) | 31 (11.15) | <0.0001 | |
| Fever >39ºC | 0 (0) | 7 (2.52) | <0.01 | |
| Asthenia | 72(25.90) | 72 (25.90) | 1 | |
| Headache | 60 (21.58) | 104 (37.41) | <0.0001 | |
| Dysthermia | 39 (14.03) | 97 (34.89) | <0.0001 | |
| Cough | 13 (4.68) | 46 (16.55) | <0.0001 | |
| Vomiting | 1 (0.36) | 16 (5.76) | <0.001 | |
| Diarrhoea | 6 (2.16) | 20 (7.19) | 0.002 | |
| Adenopathy | 11 (3.96) | 27 (9.71) | 0.002 | |
| Myalgia | 23 (8.27) | 80 (28.78) | <0.0001 | |
| Arthralgia | 16 (5.76) | 46 (16.55) | <0.0001 | |
| Antipyretic use | 44 (15.83) | 95 (34.17) | <0.0001 | |
| Urgent care need | 0 (0) | 0 (0) | ||
| Work absenteeism | 4 (1.44) | 16 (5.76) | 0.003 | |
| Post-vaccine limitation | ||||
| None (0) | 182 (65.70) | 122 (43.88) | < 0.001 | |
| Very Mild (1) | 45 (16.25) | 38 (13.67) | ||
| Mild (2) | 22 (7.94) | 34 (12.23) | ||
| Moderate (3) | 12 (4.33) | 38 (13.67) | ||
| Severe (4) | 13 (4.69) | 34 (12.23) | ||
| Very Severe (5) | 3 (1.08) | 12 (4.32) | ||